Valor Intrínseco del S&P y Nasdaq Contáctenos

Cullinan Therapeutics, Inc. CGEM NASDAQ

NASDAQ Global Select • Healthcare • Medical - Pharmaceuticals • US • USD

SharesGrow Score
60/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$30.43
+103.5%

Ha habido 50 transacciones internas recientes registradas para Cullinan Therapeutics, Inc. (CGEM), incluyendo 22 compras y 25 ventas. El total de compras internas fue valorado en $36.66M y el total de ventas internas en $1.4M.

Internos destacados con actividad reciente incluyen Michaelson Jennifer, Ahmed Nadim, Sumer Jacquelyn L. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.

Operaciones de Insiders — CGEM

Fecha Nombre Cargo Tipo de Transacción Acciones Precio Promedio Valor Acciones en Propiedad
2026-03-05 Michaelson Jennifer Chief Scientific Officer Ejercicio de Opciones (Venta) 4,000 $4.30 $17.2K 120,987
2026-02-25 Michaelson Jennifer Chief Scientific Officer Venta Informativa 1,780 $14.14 $25.17K 174,844
2026-02-24 Ahmed Nadim President and CEO Venta Informativa 13,515 $14.47 $195.56K 390,803
2026-02-24 Michaelson Jennifer Chief Scientific Officer Venta Informativa 3,601 $14.47 $52.11K 176,624
2026-02-24 Sumer Jacquelyn L Chief Legal Officer Venta Informativa 3,601 $14.47 $52.11K 128,089
2026-02-24 Jones Jeffrey Alan Chief Medical Officer Venta Informativa 4,582 $14.47 $66.3K 159,968
2026-02-23 Michaelson Jennifer Chief Scientific Officer Venta Informativa 1,752 $13.99 $24.51K 180,225
2026-02-20 Fenton Mary Kay Chief Financial Officer Venta Informativa 4,398 $13.62 $59.9K 126,380
2026-02-20 Ahmed Nadim President and CEO Venta Informativa 16,381 $13.62 $223.11K 404,318
2026-02-20 Michaelson Jennifer Chief Scientific Officer Ejercicio de Opciones (Venta) 8,000 $4.30 $34.4K 124,987
2026-02-20 Sumer Jacquelyn L Chief Legal Officer Venta Informativa 3,742 $13.62 $50.97K 131,690
2026-02-20 Jones Jeffrey Alan Chief Medical Officer Venta Informativa 4,982 $13.62 $67.85K 164,550
2026-02-18 Fenton Mary Kay Chief Financial Officer Concesión de RSU 68,750 - - 130,778
2026-02-18 Ahmed Nadim President and CEO Concesión de RSU 828,000 $12.44 $10.3M 828,000
2026-02-18 Savill Corrine Chief Business Officer Concesión de RSU 175,000 $12.44 $2.18M 175,000
2026-02-18 Michaelson Jennifer Chief Scientific Officer Concesión de RSU 115,000 $12.44 $1.43M 115,000
2026-02-18 Sumer Jacquelyn L Chief Legal Officer Concesión de RSU 230,000 $12.44 $2.86M 230,000
2026-02-18 Jones Jeffrey Alan Chief Medical Officer Concesión de RSU 300,000 $12.44 $3.73M 300,000
2026-02-12 Michaelson Jennifer Chief Scientific Officer Venta Informativa 416 $12.03 $5K 128,219
2026-01-22 Michaelson Jennifer Chief Scientific Officer Venta Informativa 4,000 $12.30 $49.2K 128,635
2025-12-31 Fenton Mary Kay Chief Financial Officer Concesión de RSU 27 $6.49 $175.23 62,028
2025-12-23 Ahmed Nadim President and CEO Venta Informativa 9,922 $10.01 $99.32K 420,699
2025-12-19 Michaelson Jennifer Chief Scientific Officer Venta Informativa 1,345 $10.01 $13.46K 132,635
2025-12-18 Michaelson Jennifer Chief Scientific Officer Venta Informativa 2,898 $9.67 $28.02K 133,980
2025-12-18 Sumer Jacquelyn L Chief Legal Officer Venta Informativa 3,480 $9.67 $33.65K 135,432
2025-12-18 Jones Jeffrey Alan Chief Medical Officer Venta Informativa 4,632 $9.67 $44.79K 169,532
2025-12-15 Michaelson Jennifer Chief Scientific Officer Venta Informativa 995 $11.90 $11.84K 136,878
2025-12-12 Michaelson Jennifer Chief Scientific Officer Venta Informativa 2,148 $12.38 $26.59K 137,873
2025-11-24 Michaelson Jennifer Chief Scientific Officer Venta Informativa 4,000 $12.30 $49.2K 138,004
2025-10-28 Lynx1 Capital Management Lp 10 Percent Owner Compra Informativa 165,667 $8.40 $1.39M 8,963,500
2025-10-17 Lynx1 Capital Management Lp 10 Percent Owner Compra Informativa 32,217 $7.84 $252.57K 8,797,833
2025-10-16 Lynx1 Capital Management Lp 10 Percent Owner Compra Informativa 150,000 $8.86 $1.33M 8,765,616
2025-10-15 Lynx1 Capital Management Lp 10 Percent Owner Compra Informativa 51,500 $7.94 $409.05K 8,615,616
2025-10-14 Lynx1 Capital Management Lp 10 Percent Owner Compra Informativa 15,032 $7.59 $114.05K 8,564,116
2025-10-10 Lynx1 Capital Management Lp 10 Percent Owner Compra Informativa 277,298 $7.36 $2.04M 8,549,084
2025-10-09 Lynx1 Capital Management Lp 10 Percent Owner Compra Informativa 626,043 $6.70 $4.19M 8,271,786
2025-10-08 Lynx1 Capital Management Lp 10 Percent Owner Desconocido - - - 7,089,443
2025-10-08 Lynx1 Capital Management Lp 10 Percent Owner Compra Informativa 556,300 $6.46 $3.59M 7,645,743
2025-08-07 Allen Andrew R Officer Desconocido - - - -
2025-08-07 Allen Andrew R Director Concesión de RSU 79,456 $7.03 $558.58K 79,456
2025-08-07 Doyle Mittie Officer Desconocido - - - -
2025-08-07 Doyle Mittie Director Concesión de RSU 79,456 $7.03 $558.58K 79,456
2025-06-12 Webster Stephen W Director Concesión de RSU 38,513 $8.95 $344.69K 38,513
2025-06-12 Rosenberg Anthony Director Concesión de RSU 38,513 $8.95 $344.69K 38,513
2025-06-12 Meek David D. Director Concesión de RSU 38,513 $8.95 $344.69K 38,513
2025-06-12 Martin Anne-marie Director Concesión de RSU 38,513 $8.95 $344.69K 38,513
2025-06-12 Ryan David P. Director Concesión de RSU 38,513 $8.95 $344.69K 38,513
2025-02-25 Ahmed Nadim President and CEO Venta Informativa 12,529 $8.53 $106.87K 430,621
2025-02-25 Michaelson Jennifer Chief Scientific Officer Venta Informativa 3,756 $8.53 $32.04K 142,004
2025-02-25 Sumer Jacquelyn L Chief Legal Officer Venta Informativa 3,756 $8.53 $32.04K 136,895
Informativa — transacción en mercado abierto (más significativa) No informativa (compra) — premio, ejercicio de opción, conversión No informativa (venta) — retención fiscal, venta de adjudicación Neutral — regalo, fideicomiso, vencimiento
Contáctenos
🎓
SharesGrow Academia
Aprende a calcular el Valor Intrínseco y encontrar acciones infravaloradas.
Sesiones semanales en vivo
Envíanos un mensaje